MAPT and Alzheimer disease: In 2018, the National Institute on Aging and the Alzheimer’s Association proposed the Research Framework classification of AD to better define the diagnosis of AD, across a disease continuum from preclinical to severe clinical stages from other LOD forms, based on the in vivo AT(N) biomarker signature, corresponding to the three landmark pathological features of increased Amyloid and Tau burden, associated with a significant loss of volume and neurodegeneration [10,11].